Document:

Document

EXHIBIT 4.1

DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
The following is a description of the common stock, par value $0.001 per share, of Varonis Systems, Inc. (the “Company,” “we” or “us”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This description is a summary and is qualified in its entirety by reference to the amended and restated certificate of incorporation and amended and restated bylaws, copies of which are filed as Exhibit 3.1 and 3.2, respectively, to the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2020 (the “2020 Annual Report”). We refer in this exhibit to our amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our amended and restated bylaws as our bylaws. 
General
Our authorized capital stock consists of 200 million shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share, all of which shares of preferred stock are undesignated.
As of December 31, 2020, 31,818,954 shares of our common stock were outstanding, and no shares of preferred stock were outstanding. 
Common Stock
Voting Rights. The holders of our common stock are entitled to one vote for each share held on all matters properly submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. All other matters, unless otherwise provided by applicable law, the rules or regulations of any stock exchange applicable to the Company, the certificate of incorporation or the bylaws (as disclosed herein), shall be decided by the affirmative vote of the holders of a majority of the voting power of the shares of stock entitled to vote thereon, regardless of whether such holders actually vote their shares on such matter or abstain from doing so.
Dividend Rights and Liquidation Rights. Holders of our common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. 
Other Rights and Preferences. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. The outstanding shares are validly issued, fully paid and non-assessable. The rights and privileges of holders of our common stock are subject to any series of preferred stock that we may issue, as described below.
Preferred Stock
Our board of directors is authorized, subject to any limitations prescribed by law, without stockholder approval, to issue from time to time up to an aggregate of 5,000,000 shares of preferred stock, in one or more series, each series to have such rights and preferences, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences as our board of directors 

determines. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of holders of any preferred stock that may be issued in the future. As of the date of the filing of the 2020 Annual Report, we had no shares of preferred stock outstanding. 
Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law
Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.
Board Composition and Filling Vacancies. Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of 75% or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum, unless otherwise determined by our board to be filled by stockholders. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors.
No Written Consent of Stockholders. Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders.
Meetings of Stockholders. Our certificate of incorporation and bylaws provide that only the chairperson of our board, the lead independent director, if any, the chief executive offer, the president or a majority of the total authorized number of directors may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.
Advance Notice Requirements. Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 75 days nor more than 105 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders’ notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.
Amendment to Certificate of Incorporation and Bylaws. Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to 
2

vote on the amendment and, if applicable, by a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, the requirements for the amendment of our bylaws, board composition (including size, classification, term, removal and vacancies), director liability and indemnification and the requirements for the amendment of our certificate of incorporation must be approved by not less than 75% of the outstanding shares entitled to vote on the amendment voting together as a single class. 
Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least 75% of the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.
Undesignated Preferred Stock. Our certificate of incorporation provides for 5,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.
Section 203 of the Delaware General Corporation Law. We are subject to the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” (any entity or person beneficially owning 15% or more of the outstanding voting stock) for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination satisfies one of the following conditions:
 
•before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
•upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or
•at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.
Section 203 defines a business combination to include:
3

 
•any merger or consolidation involving the corporation and the interested stockholder;
•any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;
•subject to exceptions, any transaction that results in the issuance of transfer by the corporation of any stock of the corporation to the interested stockholder;
•subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and
•the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

Market Listing

Our common stock is listed on The Nasdaq Global Select Market under the symbol “VRNS.”
4Exhibit 10.1

 

Second
Amendment

to

Securities
Purchase Agreement

 

This Second Amendment
To Securities Purchase Agreement (this “Amendment”) is entered into as of February 3, 2021, by and
between Medicine Man Technologies, Inc., a Nevada corporation (the “Company”), and Dye Capital Cann Holdings
II, LLC, a Delaware limited liability company (the “Buyer”). Capitalized terms used but not defined herein shall
have the meanings given them in the Purchase Agreement (as defined below).

 

RECITALS

 

WHEREAS, the
Company and the Buyer previously entered into the Securities Purchase Agreement, dated as of November 16, 2020, and the Amendment
to Securities Purchase Agreement, dated as of December 16, 2020 (as amended, the “Purchase Agreement”);

 

WHEREAS, the
Company issued and sold to the Buyer 7,700 Shares on December 16, 2020, 1,450 Shares on December 18, 2020, and 1,300 Shares on
December 22, 2020; and

 

WHEREAS, the
Company and the Buyer wish to amend the Purchase Agreement pursuant to this Amendment to provide for one or more additional Closings.

 

AGREEMENT

 

NOW, THEREFORE,
in consideration of the mutual agreements, covenants and considerations contained herein, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto agree as follows:

 

1.        Amendment
to Recital B and Section 1(a) of the Purchase Agreement. Recital B of the Purchase Agreement is hereby amended by replacing
“13,000” with “17,000” and “January 8, 2021” with “February 23, 2021” and Section
1(a) of the Purchase Agreement is hereby amended by replacing “13,000” with “17,000.”

 

2.       Receipt
of PPM Supplement. The Buyer and its advisors, if any, have been furnished with a copy of the Company’s Supplement
No. 1 to Confidential Private Placement Memorandum, dated February 2, 2021 (the “PPM Supplement”). The Buyer
understands that its investment in the Securities involves a high degree of risk, including the risks outlined in the Confidential
PPM and the PPM Supplement.

 

3.       Amendment
to Section 2(g) of the Purchase Agreement. Section 2(g) of the Purchase Agreement is hereby amended by replacing the first
sentence and the legend with the following:

 

“The Buyer understands
that the Securities are “restricted securities” under applicable federal and state securities laws and that certificates
or other instruments representing Securities except as set forth below, shall bear a restrictive legend in substantially the following
form (and a stop-transfer order may be placed against transfer of such Securities):

 

 

 

 

 

    	 	1	 

     

    

 

[NEITHER THE ISSUANCE AND SALE
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN] [THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER
(IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT
OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE
SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A FINRA REGISTERED BROKER/DEALER OR OTHER LOAN OR
FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

THE SECURITIES REPRESENTED
BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND PROVISIONS OF (A) THE ARTICLES OF INCORPORATION OF THE CORPORATION, AS AMENDED
FROM TIME TO TIME, INCLUDING, WITHOUT LIMITATION, THE CERTIFICATES OF DESIGNATION RELATING TO ALL SERIES OF PREFERRED STOCK, AND
THE RELATIVE RIGHTS, PREFERENCES, RESTRICTIONS, DESIGNATIONS, QUALIFICATIONS AND PRIVILEGES SET FORTH THEREIN AND IMPOSED THEREON
AND UPON THE HOLDERS THEREOF, AND (B) THE BYLAWS OF THE CORPORATION, AS AMENDED FROM TIME TO TIME, TO ALL OF WHICH TERMS AND PROVISIONS
THE HOLDER OF THIS CERTIFICATE, BY ACCEPTANCE HEREOF, ASSENTS.

 

THE SECURITIES REPRESENTED
BY THIS CERTIFICATE [AND THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE] ARE SUBJECT TO THE TERMS AND CONDITIONS OF
A LOCK-UP PROVISION IN THE SUBSCRIPTION AGREEMENT BETWEEN THE CORPORATION AND THE STOCKHOLDER LISTED ON THE FACE HEREOF, AS AMENDED
FROM TIME TO TIME. SUCH LOCK-UP PROVISION INCLUDES CONDITIONS AND OTHER RESTRICTIONS UPON THE TRANSFER OF THE SECURITIES REPRESENTED
BY THIS CERTIFICATE [AND THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE], INCLUDING, WITHOUT LIMITATION, AFFIRMATIVE
STEPS REQUIRED TO BE UNDERTAKEN BY ANY POTENTIAL TRANSFEREE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE AS A CONDITION TO
SUCH TRANSFER. ANY PURPORTED TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE [AND THE SECURITIES INTO WHICH THESE SECURITIES
ARE CONVERTIBLE] IN VIOLATION OF SUCH LOCK-UP PROVISION IS VOID AB INITIO.

 

COPIES OF SUCH DOCUMENTS ARE
ON FILE AT THE PRINCIPAL OFFICE OF THE CORPORATION AND ARE MADE A PART HEREOF AS THOUGH FULLY SET FORTH ON THIS CERTIFICATE.”

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	2	 

     

    

 

4.       Amendment
to Section 4(j) of the Purchase Agreement. Section 4(j) of the Purchase Agreement is hereby amended and restated in its
entirety as follows:

 

Buyers Lock-Up. Notwithstanding
anything to the contrary contained herein, the Buyer agrees that the Buyer will not (and any transferee of Shares held or formerly
held by the Buyer may not), without the prior written consent of the Company, directly or indirectly, assign, sell, pledge, contract
to sell (including any short sale), grant any option to purchase, enter into any contract to sell or otherwise dispose of or transfer
(collectively, “Transfer”) any Underlying Shares (as defined below) before and including the first anniversary
of the date of the Buyer’s acquisition of the Shares to which such Underlying Shares relate (the “Issue Date”).
Thereafter, the Buyer will only (and any transferee of Shares held or formerly held by the Buyer may only) Transfer (a) up to an
aggregate of 25% of such Underlying Shares at any time following the first anniversary of the Issue Date until the eighteen month
anniversary of the Issue Date, (b) together with any Underlying Shares Transferred under clause (a), up to an aggregate of 50%
of such Underlying Shares at any time following the eighteen month anniversary of the Issue Date until the second anniversary of
the Issue Date, and (c) all of such Underlying Shares any time following the second anniversary of the Issue Date; provided, however,
that the Buyer may Transfer all of such Underlying Shares at any time following the first Listing Event that occurs after the Issue
Date; provided further, that this Section 4(j) shall not apply to the Buyer’s Underlying Shares issued upon conversion of
Shares in connection with an Anticipated Change of Control Notice or a Forced Redemption Notice (in the latter case, solely with
respect to Underlying Shares issued upon conversion of the Shares that are the subject of such Forced Redemption Notice). The term
“Underlying Shares” means, as of any time of determination and with respect to any particular Shares, the shares
of Common Stock then-issued plus the shares of Common Stock then-remaining issuable upon conversion of such Shares in accordance
with the terms of the Certificate of Designation.

 

Any Transfer by the Buyer (or
any transferee of Shares held or formerly held by the Buyer) is subject to and conditioned upon the intended recipient’s
delivery to the Company of a written undertaking, in form and substance acceptable to the Company, pursuant to which the intended
recipient agrees to be bound by substantially the same restrictions as set forth in this Section 4(j). Any purported Transfer of
any Shares or Underlying Shares by the Buyer (or any transferee of Shares or Underlying Shares held or formerly held by the Buyer)
not made in compliance with the requirements of Section 4(j) shall be null and void ab initio, shall not be recorded on the books
of the Company or its transfer agent and shall not be recognized by the Company.

 

5.       Use
of Proceeds. The Company will use the proceeds from the Closings contemplated by this Amendment to consummate the acquisition
by the Company, or one or more wholly-owned Subsidiaries of the Company, of substantially all the assets of the Star Buds Group
stores identified as Colorado Health Consultants and Mountain View 44th (the “Star Buds Acquisitions”), and
to pay costs and expenses incurred in connection therewith and thereafter for the acquisition of additional assets of the Star
Buds Group and to pay costs and expenses incurred in connection therewith; provided that in no event may the proceeds be used,
directly or indirectly, for the redemption or repurchase of any securities of the Company or any of its Subsidiaries or repayment
of any Indebtedness.

 

6.       Conditions
to the Company’s Obligation to Sell. The obligation of the Company hereunder to issue and sell up to 6,550 Shares
to the Buyers at the Closings contemplated by this Amendment is subject to the satisfaction, at or before each Closing, of the
conditions to the Company’s obligation to sell set forth in Section 5(a) of the Agreement and each of the following conditions,
provided that all of these conditions are for the Company’s sole benefit and may be waived by the Company at any time in
its sole discretion by providing the Buyer with prior written notice thereof:

 

 

 

 

    	 	3	 

     

    

 

(a)      The
Company shall have received a waiver of certain covenants in the Securities Purchase Agreement, by and between the Company and
Dye Capital Cann Holdings, LLC, dated June 5, 2019, as amended by the Amendment to Securities Purchase Agreement, by and between
the Company and Dye Capital Cann Holdings, LLC, dated July 15, 2019, as further amended by the Amendment to Securities Purchase
Agreement, by and between the Company and Dye Capital Cann Holdings, LLC, dated May 20, 2020, and as further amended by the Consent,
Waiver and Amendment, dated December 16, 2020, to the full extent required to give effect to the Proposed Transaction (the “Second
Dye SPA Waiver”).

 

(b)      The
Company shall have received a financial fairness opinion regarding the Preferred Stock and the rights, preferences and privileges
set forth in the Certificate of Designation, acceptable to the Company in its sole discretion.

 

7.       Conditions
to the Buyer’s Obligation to Purchase. The obligation of the Buyer hereunder to purchase up to 6,550 Shares from
the Company at the Closings contemplated by this Amendment is subject to the satisfaction, at or before each Closing, of the conditions
to the Buyer’s obligation to purchase set forth in Section 6(a) of the Agreement, other than Section 6(a)(iii) and 6(a)(iv)
of the Agreement, and each of the following conditions, provided that all of these conditions are for the Buyer’s sole benefit
and may be waived by the Buyer at any time in its sole discretion by providing the Company with prior written notice thereof:

 

(a)      Other
than as set forth in a Schedules attached hereto as Attachment A, the representations and warranties of the Company shall be true
and correct as of the date when made and as of the Closing as though made at that time (except for representations and warranties
that speak as of a specific date which shall be true and correct as of such specified date) and the Company shall have performed,
satisfied and complied in all material respects with the covenants, agreements and conditions required by the Transaction Documents
to be performed, satisfied or complied with by the Company at or prior to the Closing. The Buyer shall have received a certificate,
executed by an officer of the Company, dated as of the Closing, to the foregoing effect and as to such other matters as may be
reasonably requested by the Buyer in the form attached hereto as Attachment B.

 

(b)      The
Company shall have received the Second Dye SPA Waiver.

 

(c)      All
of the conditions precedent to the obligations of the parties to the Star Buds Acquisitions to consummate the Star Buds Acquisitions
shall have been satisfied or waived, such that the Star Buds Acquisitions shall close following the funding of the purchase price
for the Shares sold in the Closing contemplated by this Amendment.

 

8.       Representations
and Warranties of the Company. The Company has the requisite corporate power and authority to enter into and perform its
obligations under this Amendment, including the Purchase Agreement as amended by this Amendment. The execution and delivery of
this Amendment and the consummation by the Company of the transactions contemplated hereby (including the Purchase Agreement as
amended by this Amendment), including, without limitation, the issuance of the Shares, have been duly authorized by the Company’s
Board of Directors and no further filing, consent or authorization is required by the Company, its Board of Directors or its stockholders.
This Amendment has been duly executed and delivered by the Company, and constitutes the legal, valid and binding obligations of
the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by general
principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to,
or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

 

 

 

    	 	4	 

     

    

 

9.       Miscellaneous.

 

(a)       This
Amendment shall be automatically effective upon the execution and delivery hereof by the Company and the Buyer.

 

(b)       All
questions concerning the construction, validity, enforcement and interpretation of this Amendment shall be governed by the internal
laws of the State of Nevada, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
of Nevada or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of
Nevada. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City
of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought
in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST,
A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AMENDMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY.

 

(d)       This
Amendment may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute
one and the same instrument. Either or both parties may execute this Amendment by facsimile signature or scanned signature in PDF
format, and any such facsimile signature or scanned signature, if identified, legible and complete, shall be deemed an original
signature and each of the parties is hereby authorized to rely thereon.

 

(e)       In
the event one or more of the provisions of this Amendment should, for any reason, be held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Amendment, and this
Amendment shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. In the event
of any inconsistencies between this Amendment and the Purchase Agreement, the terms of this Amendment shall govern. Except as set
forth above, the Purchase Agreement shall remain in full force and effect in accordance with its terms. References in the Purchase
Agreement to “this Agreement” shall mean the Purchase Agreement as amended by this Amendment, except where the context
otherwise requires.

 

(f)       The
provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns,
heirs, executors and administrators and other legal representatives.

 

[Signature Pages Follow]

 

 

 

 

    	 	5	 

     

    

 

In
Witness Whereof, the parties hereto have executed this Amendment as of the date set forth in the first paragraph above.

 

 

	 	COMPANY:
	 	 
	 	Medicine Man Technologies, Inc.
	 	 
	 	 
	 	By:/s/Nancy Huber                     
	 	Name: Nancy Huber
	 	Title: Chief Financial Officer
	 	 
	 	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Amendment
to Securities Purchase Agreement]

 

    	 	6	 

     

    

 

In
Witness Whereof, the parties hereto have executed this Amendment as of the date set forth in the first paragraph above.

 

 

	 	BUYER:
	 	 
	 	Dye Capital Cann Holdings II, LLC
	 	 
	 	 
	 	By:/s/ Justin Dye                     
	 	Name: Justin Dye
	 	Title: Authorized Person
	 	 
	 	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Amendment
to Securities Purchase Agreement]

 

 

 

 

 

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]